Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

Targeting RNA as an approach for treating retinal disease

Descripción del proyecto

DE EN ES FR IT PL

La terapia de ARN como cura para la discapacidad visual

La discapacidad visual representa un problema mundial cada vez mayor, pero todavía no existe una cura eficaz para las enfermedades de la retina (ER). El objetivo del proyecto RETORNA, financiado por las Acciones Marie Skłodowska-Curie, es encontrar un tratamiento para las ER basado en la terapia de ARN. Su propósito es crear perfiles de ARN para diferentes ER e identificar varias dianas potenciales que se utilizarán como métodos terapéuticos. Los ARN seleccionados se evaluarán para el tratamiento de diferentes ER, como la degeneración macular y la retinosis pigmentaria. El consorcio RETORNA, que incluye siete universidades y un instituto de investigación, creará una red de formación en investigación. Diez proyectos individuales serán ejecutados por diez doctorandos, cada uno de ellos bajo la tutela de científicos europeos altamente cualificados y expertos en la materia.

Objetivo

Today, vision impairment up to total blindness represents an increasing global problem with significant social and economic impact upon affected patients and society as a whole. Despite the advancing of knowledge on their genetic basis, there is no effective cure for retinal diseases (RD) to date and therefore there is an urgent need to fill this gap.

The present DN “Targeting RNA as an approach for treating retinal disease” (RETORNA) aims to treat RD by using RNA therapy. Among the research objectives, we will study different types of RNA that are expressed in retinal cells. By observing bioinformatic models, cell and tissue cultures, animal models, and human patients, we will be able to create RNA profiles for different RD. This screening will identify several targets that will be used as therapeutic approaches. Then, selected RNAs will be used to treat different RD, such as macular degeneration and retinitis pigmentosa. Furthermore, the potential economic and social impact of such strategies upon European countries will be studied, and the possibility of commercialization will be assessed.

RETORNA proposes breakthrough research, distributed in 10 individual projects, performed by 10 Doctoral Candidates (DCs). Some of the most highly qualified European scientists of the field will supervise those DCs, who will be awarded with a PhD at the end of the program. Moreover, DCs will be provided with different transferable skills, necessary for starting successful careers in academia, but also in other areas: industry, public organizations, non-profit organizations, consultancy, etc.

The RETORNA consortium consists of 8 beneficiaries, including 7 Universities and 1 Research Institute. The consortium will be managed by 5 different boards (research, managing, training, communication, and quality), all of them in continuous communication with the coordinator and with the general assembly.

Ámbito científico

Palabras clave

Programa(s)

Tema(s)

Convocatoria de propuestas

HORIZON-MSCA-2021-DN-01

Consulte otros proyectos de esta convocatoria

Régimen de financiación

HORIZON-TMA-MSCA-DN - HORIZON TMA MSCA Doctoral Networks

Coordinador

FUNDACION UNIVERSIDAD CATOLICA DE VALENCIA SAN VICENTE MARTIR
Aportación neta de la UEn
€ 503 942,40
Dirección
CALLE QUEVEDO 2
46001 Valencia
España

Ver en el mapa
Región
Este Comunitat Valenciana Valencia/València
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
Sin datos

Participantes (8)

Socios (8)

Compartir esta página

Descargar

Última actualización: 26 Agosto 2022

Mi folleto

Permalink: https://cordis.europa.eu/project/id/101073316/es

European Union, 2024